This study tests the impact of a novel invitation strategy on attendance rates to a pre-lung cancer screening lung health check appointment. Patients will be individually randomised (1:1) to receive either control invitation materials or intervention invitation materials. Those who attend will undergo a "lung health check" and be invited to a baseline screening scan if eligibility criteria are fulfilled.
Lung cancer screening using low dose computed tomography (LDCT) scans has been shown to reduce lung cancer-specific and all-cause mortality in a large United States (US) trial, and screening is now being carried out in the US. Studies have shown that participation rates are invariably low, particularly by current smokers and those from socioeconomically deprived backgrounds; groups within which high risk candidates are overrepresented. In this study the investigators aim to improve informed participation in screening and reduce socioeconomic and smoking-related biases in participation. The investigators will identify individuals at high risk of lung cancer; specifically adults aged 60-75 who are current or recent former smokers. Eligible individuals will be invited by their General Practitioner to a "lung health check appointment" via one of two randomly allocated invitation strategies. The control materials will be similar to those used by UK screening programmes for other cancer types. The intervention materials have been designed to reduce barriers to participation among smokers from low socioeconomic status backgrounds. Those that attend will have a lung cancer risk assessment, and if confirmed to be eligible, will undergo a baseline LDCT scan. Data will be collected with respect to demographics, risk and various clinical and radiological outcomes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Enrollment
1,997
In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following: 1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes 2. an invitation letter with a pre-scheduled appointment plus the same information booklet 3. a reminder re-invitation letter for those who miss their appointment without cancelling
The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
University College London Hospital NHS Trust
London, England, United Kingdom
Attendance to pre-allocated Lung Health Check Appointment
Invitation to participation in the screening pilot will take place in blocks by GP practice and occur from day 1 until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Demographics of all those invited.
Demographics of those invited to the screening pilot will take place in blocks by GP practice and occur from day 1 until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Smoking data of those attending.
This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Data on lung cancer risk of those attending.
This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Smoking data, data on lung cancer risk, symptom history and proportion of those attending that are eligible for screening.
This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Past medical and symptom history of those attending.
This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Proportion of those invited eligible for screening.
This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Uptake of CT scans and willingness to be screening
This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 1 year from the start of the study.
Psychological burden of screening
This data will be recorded at multiple timepoints following enrolment of the participant to the study. This will therefore occur from from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 18 months from the start of the study.
Informed decision making
This data will be recorded at multiple timepoints following enrolment of the participant to the study. This will therefore occur from from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).
Time frame: At an expected average of 18 months from the start of the study.
Radiological and clinical outcomes of those screened
Time frame: At an expected average of 2 years from the start of the study.
Numbers of investigations generated from screening
Time frame: At an expected average of 2 years from the start of the study.
Costs generated from screening
Time frame: At an expected average of 2 years from the start of the study.
Adverse events
Time frame: At an expected average of 2 years from the start of the study.
Mortality
Time frame: At an expected average of 2 years from the start of the study.